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In the last decade, cancer mortality has declined by approx-
imately 1% per year in both sexes in most areas of the world,
including higher- and lower-income regions [1].
However, as remarked by Vrdoljak et al. [2], appreciable
differences in cancer incidence and mortality persist through-
out various areas of the world, including Europe. In the 1990s,
after the end of nonmarket economies in most of Central and
Eastern Europe, the overall difference in cancer mortality
between Central/Eastern and Western Europe was approxi-
mately 50% in men and 30% in women, and it was more than
100% across extremes formales. In fact, in the year 2000, total
cancermortalitywas258.5deathsper100,000men inHungary
and 122.0 per 100,000 men in Sweden [3].
Some of these differences are due to risk factor ex-
posure (i.e., greater tobacco and alcohol consumption),
which caused exceedingly high lung, upper digestive, and
respiratory tract cancer mortality in Central and Eastern
Europe [4–10]. Some of the excess in Central and Eastern
Europe is due to the greater prevalence of Helicobacter
pylori infection and dietary aspects, which imply persis-
tently elevated gastric cancer mortality [11].
In Central and Eastern Europe, persistent delays and
inadequacies in cancer management exist as well. These
include inadequacies in screening and early diagnosis, which
are reflected in persistently high cervical cancer rates in those
areas of the continent [7, 12].
Furthermore, mortality from several cancers highly curable
withmedical therapies includingtesticularcancer[7,13],Hodgkin’s
lymphomas [6, 7] and leukemias [10, 14] remains higher in Central
and Eastern Europe compared with Western Europe [7], but also
compared with North America and selected major countries of
South America, including Brazil and Argentina [15]. Likewise,
although some decline in breast cancer mortality—another
neoplasm largely amendable to cure—has been observed in
recent years in Central and Eastern Europe [16], this decline has
been smaller than that inWestern Europe.
The correlation between health expenditure and
mortality-to-incidence ratio throughout Europe addressed
by Vrdoljak et al. [2] suggests that health expenditure plays a
major role in the control of cancer mortality. An increase in
cancer control expenditure would most likely have a favor-
able effect on cancermortality in Central and Eastern Europe.
However, it is now clear that countries such as Brazil and
Argentina, with gross national per capita products compara-
ble to or, in some instances, lower than those in several
Central and Eastern European countries, have achieved a
better management in highly treatable cancers, such as
Hodgkin’s lymphoma [15] than that achieved by several
countries in Central and Eastern Europe. Besides expendi-
ture, therefore, several measures aimed at improving clinical
management (addressing gaps in specialty trainingand facilities
from pathological diagnosis to multidisciplinary treatments),
and optimizing cancer control (such as antismoking measures),
as outlined by Vrdoljak et al. [2], are required to reduce cancer
rates in Central and Eastern Europe to levels comparable with
those in other high-income countries.
More than a generation has now passed since the end of
nonmarket economies in Central and Eastern Europe. It is time
for this area of the continent to close the gap in cancer
incidence and mortality rates with Western Europe and other
high-income areas of the world [17, 18].
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